Skip to main content
Erschienen in: Clinical and Experimental Medicine 2/2018

22.09.2017 | Review Article

Ocular adnexal marginal zone lymphoma of mucosa-associated lymphoid tissue

verfasst von: Dimitrios Kalogeropoulos, Alexandra Papoudou-Bai, Panagiotis Kanavaros, Chris Kalogeropoulos

Erschienen in: Clinical and Experimental Medicine | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Ocular adnexal lymphomas are a group of heterogeneous neoplasms representing approximately 1–2% of non-Hodgkin lymphomas and 8% of extranodal lymphomas. The incidence of primary ocular adnexal lymphoid tumors has raised over the last decades, and this could be probably attributed to the more sophisticated diagnostic techniques. Due to the wide spectrum of clinical manifestations, ocular tissue biopsy is important in order to set a precise diagnosis based on histological, immunophenotypical and, in some cases, molecular findings. The most common subtype, which may account for up to 80% of primary ocular adnexal lymphomas, is extranodal marginal zone lymphoma (EMZL) of mucosa-associated lymphoid tissue. This lymphoma is usually asymptomatic in the early phase of the disease causing a delay in the final diagnosis and prompt therapy. The pathogenesis of a proportion of these tumors has been linked to chronic inflammatory stimulation from specific infectious factors (e.g., Chlamydia psittaci) or to autoimmunity. The further improvement in diagnostic methods and the further understanding of the pathogenesis of ocular adnexal EMZL may contribute to the establishment of a more successful multidisciplinary therapeutic planning.
Literatur
3.
Zurück zum Zitat Chan CC. Primary intraocular lymphoma: clinical features, diagnosis, and treatment. Clin Lymphoma. 2003;4(1):30–1.PubMedCrossRef Chan CC. Primary intraocular lymphoma: clinical features, diagnosis, and treatment. Clin Lymphoma. 2003;4(1):30–1.PubMedCrossRef
4.
Zurück zum Zitat Coupland SE, Damato B. Understanding intraocular lymphomas. Clin Exp Ophthalmol. 2008;36(6):564–78.PubMedCrossRef Coupland SE, Damato B. Understanding intraocular lymphomas. Clin Exp Ophthalmol. 2008;36(6):564–78.PubMedCrossRef
5.
6.
Zurück zum Zitat White WL, Ferry JA, Harris NL, Grove AS Jr. Ocular adnexal lymphoma. A clinicopathologic study with identification of lymphomas of mucosa-associated lymphoid tissue type. Ophthalmology. 1995;102(12):1994–2006.PubMedCrossRef White WL, Ferry JA, Harris NL, Grove AS Jr. Ocular adnexal lymphoma. A clinicopathologic study with identification of lymphomas of mucosa-associated lymphoid tissue type. Ophthalmology. 1995;102(12):1994–2006.PubMedCrossRef
7.
Zurück zum Zitat Coupland SE, Krause L, Delecluse HJ, et al. Lymphoproliferative lesions of the ocular adnexa. Analysis of 112 cases. Ophthalmology. 1998;105(8):1430–41.PubMedCrossRef Coupland SE, Krause L, Delecluse HJ, et al. Lymphoproliferative lesions of the ocular adnexa. Analysis of 112 cases. Ophthalmology. 1998;105(8):1430–41.PubMedCrossRef
8.
Zurück zum Zitat Cho EY, Han JJ, Ree HJ, et al. Clinicopathologic analysis of ocular adnexal lymphomas: extranodal marginal zone b-cell lymphoma constitutes the vast majority of ocular lymphomas among Koreans and affects younger patients. Am J Hematol. 2003;73(2):87–96.PubMedCrossRef Cho EY, Han JJ, Ree HJ, et al. Clinicopathologic analysis of ocular adnexal lymphomas: extranodal marginal zone b-cell lymphoma constitutes the vast majority of ocular lymphomas among Koreans and affects younger patients. Am J Hematol. 2003;73(2):87–96.PubMedCrossRef
9.
Zurück zum Zitat Ferry JA, Fung CY, Zukerberg L, et al. Lymphoma of the ocular adnexa: a study of 353 cases. Am J Surg Pathol. 2007;31(2):170–84.PubMedCrossRef Ferry JA, Fung CY, Zukerberg L, et al. Lymphoma of the ocular adnexa: a study of 353 cases. Am J Surg Pathol. 2007;31(2):170–84.PubMedCrossRef
11.
Zurück zum Zitat Knowles DM, Jakobiec FA, McNally L, Burke JS. Lymphoid hyperplasia and malignant lymphoma occurring in the ocular adnexa (orbit, conjunctiva, and eyelids): a prospective multiparametric analysis of 108 cases during 1977–1987. Hum Pathol. 1990;21:959–73.PubMedCrossRef Knowles DM, Jakobiec FA, McNally L, Burke JS. Lymphoid hyperplasia and malignant lymphoma occurring in the ocular adnexa (orbit, conjunctiva, and eyelids): a prospective multiparametric analysis of 108 cases during 1977–1987. Hum Pathol. 1990;21:959–73.PubMedCrossRef
12.
Zurück zum Zitat Mannami T, Yoshino T, Oshima K, et al. Clinical, histopathological, and immunogenetic analysis of ocular adnexal lymphoproliferative disorders: characterization of malt lymphoma and reactive lymphoid hyperplasia. Mod Pathol. 2001;14:641–9.PubMedCrossRef Mannami T, Yoshino T, Oshima K, et al. Clinical, histopathological, and immunogenetic analysis of ocular adnexal lymphoproliferative disorders: characterization of malt lymphoma and reactive lymphoid hyperplasia. Mod Pathol. 2001;14:641–9.PubMedCrossRef
13.
Zurück zum Zitat Auw-Haedrich C, Coupland SE, Kapp A, et al. Long term outcome of ocular adnexal lymphoma subtyped according to the REAL classification. Revised European and American Lymphoma. Br J Ophthalmol. 2001;85:63–9.PubMedPubMedCentralCrossRef Auw-Haedrich C, Coupland SE, Kapp A, et al. Long term outcome of ocular adnexal lymphoma subtyped according to the REAL classification. Revised European and American Lymphoma. Br J Ophthalmol. 2001;85:63–9.PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Ferreri AJ, Dolcetti R, Du M, et al. Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphoma-genesis and microbial-targeted therapy. Ann Oncol. 2008;19:835–46.PubMedCrossRef Ferreri AJ, Dolcetti R, Du M, et al. Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphoma-genesis and microbial-targeted therapy. Ann Oncol. 2008;19:835–46.PubMedCrossRef
16.
Zurück zum Zitat Woo JM, Tang CK, Rho MS, Lee JH, Kwon HC, Ahn HB. The clinical characteristics and treatment results of ocular adnexal lymphoma. Korean J Ophthalmol. 2006;20:7–12.PubMedPubMedCentralCrossRef Woo JM, Tang CK, Rho MS, Lee JH, Kwon HC, Ahn HB. The clinical characteristics and treatment results of ocular adnexal lymphoma. Korean J Ophthalmol. 2006;20:7–12.PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Nakata M, Matsuno Y, Katsumata N, et al. Histology according to the revised European-American lymphoma classification significantly predicts the prognosis of ocular adnexal lymphoma. Leuk Lymphoma. 1999;32:533–43.PubMedCrossRef Nakata M, Matsuno Y, Katsumata N, et al. Histology according to the revised European-American lymphoma classification significantly predicts the prognosis of ocular adnexal lymphoma. Leuk Lymphoma. 1999;32:533–43.PubMedCrossRef
18.
Zurück zum Zitat Tanimoto K, Kaneko A, Suzuki S, et al. Primary ocular adnexal MALT lymphoma: a long-term follow- up study of 114 patients. Jpn J Clin Oncol. 2007;37:337–44.PubMedCrossRef Tanimoto K, Kaneko A, Suzuki S, et al. Primary ocular adnexal MALT lymphoma: a long-term follow- up study of 114 patients. Jpn J Clin Oncol. 2007;37:337–44.PubMedCrossRef
19.
Zurück zum Zitat Decaudin D, de Cremoux P, Vincent-Salomon A, et al. Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options. Blood. 2006;108:1451–60.PubMedCrossRef Decaudin D, de Cremoux P, Vincent-Salomon A, et al. Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options. Blood. 2006;108:1451–60.PubMedCrossRef
20.
Zurück zum Zitat Shields CL, Shields JA, Carvalho C, et al. Conjunctival lymphoid tumors: clinical analysis of 117 cases and relationship to systemic lymphoma. Ophthalmology. 2001;108:979–84.PubMedCrossRef Shields CL, Shields JA, Carvalho C, et al. Conjunctival lymphoid tumors: clinical analysis of 117 cases and relationship to systemic lymphoma. Ophthalmology. 2001;108:979–84.PubMedCrossRef
21.
Zurück zum Zitat Johnson TE, Tse DT, Byrne GE Jr, et al. Ocular-adnexal lymphoid tumors: a clinicopathologic and molecular genetic study of 77 patients. Ophthal Plast Reconstr Surg. 1999;15:171–9.PubMedCrossRef Johnson TE, Tse DT, Byrne GE Jr, et al. Ocular-adnexal lymphoid tumors: a clinicopathologic and molecular genetic study of 77 patients. Ophthal Plast Reconstr Surg. 1999;15:171–9.PubMedCrossRef
22.
Zurück zum Zitat Lagoo AS, Haggerty C, Kim Y, et al. Morphologic features of 115 lymphomas of the orbit and ocular adnexa categorized according to the World Health Organization classification. Are marginal zone lymphomas in the orbit mucosa-associated lymphoid tissue-type lymphomas? Arch Pathol Lab Med. 2008;132:1405–15.PubMed Lagoo AS, Haggerty C, Kim Y, et al. Morphologic features of 115 lymphomas of the orbit and ocular adnexa categorized according to the World Health Organization classification. Are marginal zone lymphomas in the orbit mucosa-associated lymphoid tissue-type lymphomas? Arch Pathol Lab Med. 2008;132:1405–15.PubMed
23.
Zurück zum Zitat Coupland SE, Damato B. Lymphomas involving the eye and the ocular adnexa. Curr Opin Ophthalmol. 2006;17:523–31.PubMed Coupland SE, Damato B. Lymphomas involving the eye and the ocular adnexa. Curr Opin Ophthalmol. 2006;17:523–31.PubMed
24.
Zurück zum Zitat Coupland SE, Hellmich M, Auw-Haedrich C, Lee WR, Stein H. Prognostic value of cell-cycle markers in ocular adnexal lymphoma: an assessment of 230 cases. Graefes Arch Clin Exp Ophthalmol. 2004;242:130–45.PubMedCrossRef Coupland SE, Hellmich M, Auw-Haedrich C, Lee WR, Stein H. Prognostic value of cell-cycle markers in ocular adnexal lymphoma: an assessment of 230 cases. Graefes Arch Clin Exp Ophthalmol. 2004;242:130–45.PubMedCrossRef
25.
Zurück zum Zitat Annibali O, Sabatino F, Mantelli F, Olimpieri O, Bonini S, Avvisati G. Review article: mucosa-associated lymphoid tissue (MALT)-type lymphoma of ocular adnexa. Biology and treatment. Crit Rev Oncol Hematol. 2016;100:37–45.PubMedCrossRef Annibali O, Sabatino F, Mantelli F, Olimpieri O, Bonini S, Avvisati G. Review article: mucosa-associated lymphoid tissue (MALT)-type lymphoma of ocular adnexa. Biology and treatment. Crit Rev Oncol Hematol. 2016;100:37–45.PubMedCrossRef
26.
Zurück zum Zitat Middle Stephen, Coupland Sarah E, Taktak Azzam, et al. Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin’s lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1-phosphate receptors and integrins. Exp Hematol Oncol. 2015;4:10. doi:10.1186/s40164-015-0004-3.PubMedPubMedCentralCrossRef Middle Stephen, Coupland Sarah E, Taktak Azzam, et al. Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin’s lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1-phosphate receptors and integrins. Exp Hematol Oncol. 2015;4:10. doi:10.​1186/​s40164-015-0004-3.PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat Bai M, Tsanou E, Agnantis NJ, Kamina S, et al. Proliferation profile of classical Hodgkin’s lymphomas. Increased expression of the protein cyclin D2 in Hodgkin’s and Reed-Sternberg cells. Mod Pathol. 2004;17(11):1338–45.PubMedCrossRef Bai M, Tsanou E, Agnantis NJ, Kamina S, et al. Proliferation profile of classical Hodgkin’s lymphomas. Increased expression of the protein cyclin D2 in Hodgkin’s and Reed-Sternberg cells. Mod Pathol. 2004;17(11):1338–45.PubMedCrossRef
28.
Zurück zum Zitat Bai M, Skyrlas A, Agnantis NJ, et al. Diffuse large B-cell lymphomas with germinal center B-cell-like differentiation immunophenotypic profile are associated with high apoptotic index, high expression of the proapoptotic proteins bax, bak and bid and low expression of the antiapoptotic protein bcl-xl. Mod Pathol. 2004;17(7):847–56.PubMedCrossRef Bai M, Skyrlas A, Agnantis NJ, et al. Diffuse large B-cell lymphomas with germinal center B-cell-like differentiation immunophenotypic profile are associated with high apoptotic index, high expression of the proapoptotic proteins bax, bak and bid and low expression of the antiapoptotic protein bcl-xl. Mod Pathol. 2004;17(7):847–56.PubMedCrossRef
29.
Zurück zum Zitat Bai M, Agnantis NJ, Skyrlas A, et al. Increased expression of the bcl6 and CD10 proteins is associated with increased apoptosis and proliferation in diffuse large B-cell lymphomas. Mod Pathol. 2003;16(5):471–80.PubMedCrossRef Bai M, Agnantis NJ, Skyrlas A, et al. Increased expression of the bcl6 and CD10 proteins is associated with increased apoptosis and proliferation in diffuse large B-cell lymphomas. Mod Pathol. 2003;16(5):471–80.PubMedCrossRef
30.
Zurück zum Zitat Bai M, Vlachonikolis J, Agnantis NJ, et al. Low expression of p27 protein combined with altered p53 and Rb/p16 expression status is associated with increased expression of cyclin A and cyclin B1 in diffuse large B-cell lymphomas. Mod Pathol. 2001;14(11):1105–13.PubMedCrossRef Bai M, Vlachonikolis J, Agnantis NJ, et al. Low expression of p27 protein combined with altered p53 and Rb/p16 expression status is associated with increased expression of cyclin A and cyclin B1 in diffuse large B-cell lymphomas. Mod Pathol. 2001;14(11):1105–13.PubMedCrossRef
31.
Zurück zum Zitat Franco R, Camacho FI, Caleo A, et al. Nuclear bcl10 expression characterizes a group of ocular adnexa MALT lymphomas with shorter failure-free survival. Mod Pathol. 2006;19(8):1055–67.PubMedCrossRef Franco R, Camacho FI, Caleo A, et al. Nuclear bcl10 expression characterizes a group of ocular adnexa MALT lymphomas with shorter failure-free survival. Mod Pathol. 2006;19(8):1055–67.PubMedCrossRef
32.
Zurück zum Zitat Tanimoto K, Sekiguchi N, Yokota Y, et al. Fluorescence in situ hybridization (FISH) analysis of primary ocular adnexal MALT lymphoma. BMC Cancer. 2006;6:249.PubMedPubMedCentralCrossRef Tanimoto K, Sekiguchi N, Yokota Y, et al. Fluorescence in situ hybridization (FISH) analysis of primary ocular adnexal MALT lymphoma. BMC Cancer. 2006;6:249.PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Streubel B, Lamprecht A, Dierlamm J, et al. T(14;18) (q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood. 2003;101:2335–9.PubMedCrossRef Streubel B, Lamprecht A, Dierlamm J, et al. T(14;18) (q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood. 2003;101:2335–9.PubMedCrossRef
34.
Zurück zum Zitat Kim WS, Honma K, Karnan S, et al. Genome wide array-based comparative genomic hybridization of ocular marginal zone B cell lymphoma: comparison with pulmonary and nodal marginal zone B cell lymphoma. Genes Chromosomes Cancer. 2007;46:776–83.PubMedCrossRef Kim WS, Honma K, Karnan S, et al. Genome wide array-based comparative genomic hybridization of ocular marginal zone B cell lymphoma: comparison with pulmonary and nodal marginal zone B cell lymphoma. Genes Chromosomes Cancer. 2007;46:776–83.PubMedCrossRef
35.
Zurück zum Zitat Schiby G, Polak-Charcon S, Mardoukh C, et al. Orbital marginal zone lymphomas: an immunohistochemical, polymerase chain reaction, and fluorescence in situ hybridization study. Hum Pathol. 2007;38:435–42.PubMedCrossRef Schiby G, Polak-Charcon S, Mardoukh C, et al. Orbital marginal zone lymphomas: an immunohistochemical, polymerase chain reaction, and fluorescence in situ hybridization study. Hum Pathol. 2007;38:435–42.PubMedCrossRef
36.
Zurück zum Zitat Matteucci C, Galieni P, Leoncini L, et al. Typical genomic imbalances in primary MALT lymphoma of the orbit. J Pathol. 2003;200:656–60.PubMedCrossRef Matteucci C, Galieni P, Leoncini L, et al. Typical genomic imbalances in primary MALT lymphoma of the orbit. J Pathol. 2003;200:656–60.PubMedCrossRef
37.
Zurück zum Zitat Wotherspoon AC, Pan LX, Diss TC, Isaacson PG. Cytogenetic study of B-cell lymphoma of mucosa-associated lymphoid tissue. Cancer Genet Cytogenet. 1992;58:35–8.PubMedCrossRef Wotherspoon AC, Pan LX, Diss TC, Isaacson PG. Cytogenetic study of B-cell lymphoma of mucosa-associated lymphoid tissue. Cancer Genet Cytogenet. 1992;58:35–8.PubMedCrossRef
38.
Zurück zum Zitat Ye H, Liu H, Attygalle A, et al. Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H pylori in gastric MALT lymphoma. Blood. 2003;102:1012–8.PubMedCrossRef Ye H, Liu H, Attygalle A, et al. Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H pylori in gastric MALT lymphoma. Blood. 2003;102:1012–8.PubMedCrossRef
39.
Zurück zum Zitat Streubel B, Simonitsch-Klupp I, Mullauer L, et al. Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia. 2004;18:1722–6.PubMedCrossRef Streubel B, Simonitsch-Klupp I, Mullauer L, et al. Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia. 2004;18:1722–6.PubMedCrossRef
40.
Zurück zum Zitat Akagi T, Motegi M, Tamura A, et al. A novel gene, MALT1 et 18q21, is involved in t(11;18)(q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene. 1999;18:5785–94.PubMedCrossRef Akagi T, Motegi M, Tamura A, et al. A novel gene, MALT1 et 18q21, is involved in t(11;18)(q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene. 1999;18:5785–94.PubMedCrossRef
41.
Zurück zum Zitat Streubel B, Vinatzer U, Lamprecht A, Raderer M, Chott A. T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia. 2005;19:652–8.PubMedCrossRef Streubel B, Vinatzer U, Lamprecht A, Raderer M, Chott A. T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia. 2005;19:652–8.PubMedCrossRef
42.
Zurück zum Zitat Willis T, Jadayel DM, Du MQ, et al. Bcl10 is involved int (1; 14) (p22; q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell. 1999;96:35–45.PubMedCrossRef Willis T, Jadayel DM, Du MQ, et al. Bcl10 is involved int (1; 14) (p22; q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell. 1999;96:35–45.PubMedCrossRef
44.
48.
Zurück zum Zitat Du MQ. MALT lymphoma: recent advances in aetiology and molecular genetics. J Clin Exp Hematopathol. 2007;47:31–42.CrossRef Du MQ. MALT lymphoma: recent advances in aetiology and molecular genetics. J Clin Exp Hematopathol. 2007;47:31–42.CrossRef
51.
Zurück zum Zitat Inokuchi M, Ito T, Uchikoshi M, et al. Infection of B cells with hepatitis C virus for the development of lymphoproliferative disorders in patients with chronic hepatitis C. J Med Virol. 2009;81(4):619–27. doi:10.1002/jmv.21388.PubMedCrossRef Inokuchi M, Ito T, Uchikoshi M, et al. Infection of B cells with hepatitis C virus for the development of lymphoproliferative disorders in patients with chronic hepatitis C. J Med Virol. 2009;81(4):619–27. doi:10.​1002/​jmv.​21388.PubMedCrossRef
53.
59.
Zurück zum Zitat Chanudet E, Zhou Y, Bacon CM, et al. Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions. J Pathol. 2006;209(3):344–51. doi:10.1002/path.1984.PubMedCrossRef Chanudet E, Zhou Y, Bacon CM, et al. Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions. J Pathol. 2006;209(3):344–51. doi:10.​1002/​path.​1984.PubMedCrossRef
62.
Zurück zum Zitat Decaudin D, Dolcetti R, de Cremoux P, et al. Variable association between Chlamydophila psittaci infection and ocular adnexal lymphomas: methodological biases or true geographical variations? Anticancer Drugs. 2008;19(8):761–5. doi:10.1097/CAD.0b013e32830b58c4.PubMedCrossRef Decaudin D, Dolcetti R, de Cremoux P, et al. Variable association between Chlamydophila psittaci infection and ocular adnexal lymphomas: methodological biases or true geographical variations? Anticancer Drugs. 2008;19(8):761–5. doi:10.​1097/​CAD.​0b013e32830b58c4​.PubMedCrossRef
63.
Zurück zum Zitat Usui Y, Rao NA, Takase H, et al. Comprehensive polymerase chain reaction assay for detection of pathogenic DNA in lymphoproliferative disorders of the ocular adnexa. Nat Sci Rep. 2016;. doi:10.1038/srep36621.CrossRef Usui Y, Rao NA, Takase H, et al. Comprehensive polymerase chain reaction assay for detection of pathogenic DNA in lymphoproliferative disorders of the ocular adnexa. Nat Sci Rep. 2016;. doi:10.​1038/​srep36621.CrossRef
64.
Zurück zum Zitat Flanders AE, Espinosa GA, Markiewicz DA, Howell DD. Orbital lymphoma. Role of CT and MRI. Radiol Clin North Am. 1987;25:601–13.PubMed Flanders AE, Espinosa GA, Markiewicz DA, Howell DD. Orbital lymphoma. Role of CT and MRI. Radiol Clin North Am. 1987;25:601–13.PubMed
65.
Zurück zum Zitat Polito E, Leccisotti A, Galieni P. Clinical and radiological presentation of 95 orbital lymphoid tumors. Graefe Arch Clin Exp Ophthalmol. 1996;234:504–9.CrossRef Polito E, Leccisotti A, Galieni P. Clinical and radiological presentation of 95 orbital lymphoid tumors. Graefe Arch Clin Exp Ophthalmol. 1996;234:504–9.CrossRef
66.
Zurück zum Zitat Valenzuela AA, Allen C, Grimes D, Wong D, Sullivan TJ. Positron emission tomography in the detection and staging of ocular adnexal lymphoproliferative disease. Ophthalmology. 2006;113:2331–7.PubMedCrossRef Valenzuela AA, Allen C, Grimes D, Wong D, Sullivan TJ. Positron emission tomography in the detection and staging of ocular adnexal lymphoproliferative disease. Ophthalmology. 2006;113:2331–7.PubMedCrossRef
67.
Zurück zum Zitat Sullivan TJ, Valenzuela AA. Imaging features of ocular adnexal lymphoproliferative disease. Eye. 2006;20:1189–95.PubMedCrossRef Sullivan TJ, Valenzuela AA. Imaging features of ocular adnexal lymphoproliferative disease. Eye. 2006;20:1189–95.PubMedCrossRef
68.
Zurück zum Zitat Gayed I, Eskandari MF, McLaughlin P, Pro B, Diba R, Esmaeli B. Value of positron emission tomography in staging ocular adnexal lymphomas and evaluating their response to therapy. Ophthalmic Surg Lasers Imaging. 2007;38:319–25.PubMed Gayed I, Eskandari MF, McLaughlin P, Pro B, Diba R, Esmaeli B. Value of positron emission tomography in staging ocular adnexal lymphomas and evaluating their response to therapy. Ophthalmic Surg Lasers Imaging. 2007;38:319–25.PubMed
69.
Zurück zum Zitat Kennerdell JS, Flores NE, Hartsock RJ. Low-dose radiotherapy for lymphoid lesions of the orbit and ocular adnexa. Ophthal Plast Reconstr Surg. 1999;15:129–33.PubMedCrossRef Kennerdell JS, Flores NE, Hartsock RJ. Low-dose radiotherapy for lymphoid lesions of the orbit and ocular adnexa. Ophthal Plast Reconstr Surg. 1999;15:129–33.PubMedCrossRef
70.
Zurück zum Zitat Coupland SE, Hummel M, Stein H. Ocular adnexal lymphomas: five case presentations and a review of the literature. Surv Ophthalmol. 2002;47(5):470–90.PubMedCrossRef Coupland SE, Hummel M, Stein H. Ocular adnexal lymphomas: five case presentations and a review of the literature. Surv Ophthalmol. 2002;47(5):470–90.PubMedCrossRef
71.
72.
Zurück zum Zitat Jenkins C, Rose GE, Bunce C, et al. Histological features of ocular adnexal lymphoma (REAL classification) and their association with patient morbidity and survival. Br J Ophthalmol. 2000;84:907–13.PubMedPubMedCentralCrossRef Jenkins C, Rose GE, Bunce C, et al. Histological features of ocular adnexal lymphoma (REAL classification) and their association with patient morbidity and survival. Br J Ophthalmol. 2000;84:907–13.PubMedPubMedCentralCrossRef
73.
Zurück zum Zitat Tanimoto K, Kaneko A, Suzuki S, et al. Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma. Ann Oncol. 2006;17:135–40.PubMedCrossRef Tanimoto K, Kaneko A, Suzuki S, et al. Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma. Ann Oncol. 2006;17:135–40.PubMedCrossRef
74.
Zurück zum Zitat Lee JL, Kim MK, Lee KH, et al. Extranodal marginal zone B-cell lymphomas of mucosa associated lymphoid tissue-type of the orbit and ocular adnexa. Ann Hematol. 2005;84:13–8.PubMedCrossRef Lee JL, Kim MK, Lee KH, et al. Extranodal marginal zone B-cell lymphomas of mucosa associated lymphoid tissue-type of the orbit and ocular adnexa. Ann Hematol. 2005;84:13–8.PubMedCrossRef
75.
Zurück zum Zitat Restrepo A, Raez LE, Byrne GE Jr, et al. Is central nervous system prophylaxis necessary in ocular adnexal lymphoma? Crit Rev Oncog. 1998;9:269–73.PubMed Restrepo A, Raez LE, Byrne GE Jr, et al. Is central nervous system prophylaxis necessary in ocular adnexal lymphoma? Crit Rev Oncog. 1998;9:269–73.PubMed
76.
Zurück zum Zitat Sasai K, Yamabe H, Dodo Y, Kashii S, Nagata Y, Hiraoka M. Non-Hodgkin’s lymphoma of the ocular adnexa. Acta Oncol. 2001;40:485–90.PubMedCrossRef Sasai K, Yamabe H, Dodo Y, Kashii S, Nagata Y, Hiraoka M. Non-Hodgkin’s lymphoma of the ocular adnexa. Acta Oncol. 2001;40:485–90.PubMedCrossRef
77.
Zurück zum Zitat Bolek TW, Moyses HM, Marcus RB Jr, et al. Radiotherapy in the management of orbital lymphoma. Int J Radiat Oncol Biol Phys. 1999;44:31–6.PubMedCrossRef Bolek TW, Moyses HM, Marcus RB Jr, et al. Radiotherapy in the management of orbital lymphoma. Int J Radiat Oncol Biol Phys. 1999;44:31–6.PubMedCrossRef
78.
Zurück zum Zitat Le QT, Eulau SM, George TI, et al. Primary radiotherapy for localized orbital MALT lymphoma. Int J Radiat Oncol Biol Phys. 2002;52:657–63.PubMedCrossRef Le QT, Eulau SM, George TI, et al. Primary radiotherapy for localized orbital MALT lymphoma. Int J Radiat Oncol Biol Phys. 2002;52:657–63.PubMedCrossRef
79.
Zurück zum Zitat Liao SL, Kao SC, Hou PK, Chen MS. Results of radiotherapy for orbital and adnexal lymphoma. Orbit. 2002;21:117–23.PubMedCrossRef Liao SL, Kao SC, Hou PK, Chen MS. Results of radiotherapy for orbital and adnexal lymphoma. Orbit. 2002;21:117–23.PubMedCrossRef
80.
Zurück zum Zitat Hasegawa M, Kojima M, Shioya M, et al. Treatment results of radiotherapy for malignant lymphoma of the orbit and histopathologic review according to the WHO classification. Int J Radiat Oncol Biol Phys. 2003;57:172–6.PubMedCrossRef Hasegawa M, Kojima M, Shioya M, et al. Treatment results of radiotherapy for malignant lymphoma of the orbit and histopathologic review according to the WHO classification. Int J Radiat Oncol Biol Phys. 2003;57:172–6.PubMedCrossRef
81.
Zurück zum Zitat Stafford SL, Kozelsky TF, Garrity JA, et al. Orbital lymphoma: radiotherapy outcome and complications. Radiother Oncol. 2001;59:139–44.PubMedCrossRef Stafford SL, Kozelsky TF, Garrity JA, et al. Orbital lymphoma: radiotherapy outcome and complications. Radiother Oncol. 2001;59:139–44.PubMedCrossRef
82.
Zurück zum Zitat Uno T, Isobe K, Shikama N, et al. Radiotherapy for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa: a multiinstitutional, retrospective review of 50 patients. Cancer. 2003;98:865–71.PubMedCrossRef Uno T, Isobe K, Shikama N, et al. Radiotherapy for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa: a multiinstitutional, retrospective review of 50 patients. Cancer. 2003;98:865–71.PubMedCrossRef
83.
Zurück zum Zitat Ejima Y, Sasaki R, Okamoto Y, et al. Ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy. Radiother Oncol. 2006;78:6–9.PubMedCrossRef Ejima Y, Sasaki R, Okamoto Y, et al. Ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy. Radiother Oncol. 2006;78:6–9.PubMedCrossRef
84.
Zurück zum Zitat Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol. 2003;21:4157–64.PubMedCrossRef Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol. 2003;21:4157–64.PubMedCrossRef
85.
Zurück zum Zitat McKelvie PA, McNab A, Francis IC, Fox R, O’Day J. Ocular adnexal lymphoproliferative disease: a series of 73 cases. Clin Exp Ophthalmol. 2001;29:387–93.PubMedCrossRef McKelvie PA, McNab A, Francis IC, Fox R, O’Day J. Ocular adnexal lymphoproliferative disease: a series of 73 cases. Clin Exp Ophthalmol. 2001;29:387–93.PubMedCrossRef
86.
Zurück zum Zitat Galieni P, Polito E, Leccisotti A, et al. Localized orbital lymphoma. Haematologica. 1997;82:436–9.PubMed Galieni P, Polito E, Leccisotti A, et al. Localized orbital lymphoma. Haematologica. 1997;82:436–9.PubMed
87.
Zurück zum Zitat Ben Simon GJ, Cheung N, McKelvie P, Fox R, McNab AA. Oral chlorambucil for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue of the orbit. Ophthalmology. 2006;113:1209–13.PubMedCrossRef Ben Simon GJ, Cheung N, McKelvie P, Fox R, McNab AA. Oral chlorambucil for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue of the orbit. Ophthalmology. 2006;113:1209–13.PubMedCrossRef
88.
Zurück zum Zitat Charlotte F, Doghmi K, Cassoux N, et al. Ocular adnexal marginal zone B cell lymphoma: a clinical and pathologic study of 23 cases. Virchows Arch. 2006;448:506–16.PubMedCrossRef Charlotte F, Doghmi K, Cassoux N, et al. Ocular adnexal marginal zone B cell lymphoma: a clinical and pathologic study of 23 cases. Virchows Arch. 2006;448:506–16.PubMedCrossRef
89.
Zurück zum Zitat Song EK, Kim SY, Kim TM, et al. Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma. Ann Oncol. 2008;19:242–6.PubMedCrossRef Song EK, Kim SY, Kim TM, et al. Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma. Ann Oncol. 2008;19:242–6.PubMedCrossRef
90.
Zurück zum Zitat Rigacci L, Nassi L, Puccioni M, et al. Rituximab and chlorambucil as first-line treatment for low grade ocular adnexal lymphomas. Ann Hematol. 2007;86:565–8.PubMedCrossRef Rigacci L, Nassi L, Puccioni M, et al. Rituximab and chlorambucil as first-line treatment for low grade ocular adnexal lymphomas. Ann Hematol. 2007;86:565–8.PubMedCrossRef
91.
Zurück zum Zitat Avilés A, Neri N, Calva A, Huerta-Guzmán J, Cleto S, Nambo MJ. Addition of a short course of chemotherapy did not improve outcome in patients with localized marginal B-cell lymphoma of the orbit. Oncology. 2006;70:173–6.PubMedCrossRef Avilés A, Neri N, Calva A, Huerta-Guzmán J, Cleto S, Nambo MJ. Addition of a short course of chemotherapy did not improve outcome in patients with localized marginal B-cell lymphoma of the orbit. Oncology. 2006;70:173–6.PubMedCrossRef
92.
Zurück zum Zitat Blasi MA, Gherlinzoni F, Calvisi G, et al. Local chemotherapy with interferon-alpha for conjunctival mucosa-associated lymphoid tissue lymphoma: a preliminary report. Ophthalmology. 2001;108:559–62.PubMedCrossRef Blasi MA, Gherlinzoni F, Calvisi G, et al. Local chemotherapy with interferon-alpha for conjunctival mucosa-associated lymphoid tissue lymphoma: a preliminary report. Ophthalmology. 2001;108:559–62.PubMedCrossRef
93.
Zurück zum Zitat Di Gaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity either drug alone. Br J Haematol. 2001;114:800–9.PubMedCrossRef Di Gaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity either drug alone. Br J Haematol. 2001;114:800–9.PubMedCrossRef
94.
Zurück zum Zitat Reff ME, Carner K, Chambers KS, et al. Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435–45.PubMed Reff ME, Carner K, Chambers KS, et al. Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435–45.PubMed
95.
Zurück zum Zitat Sacchi S, Federico M, Vitolo U, et al. Clinical activity and safety of combination immunotherapy with IFN-2a and rituximab in patients with re-lapsed low grade non-Hodgkin’s lymphoma. Haematologica. 2001;86:951–8.PubMed Sacchi S, Federico M, Vitolo U, et al. Clinical activity and safety of combination immunotherapy with IFN-2a and rituximab in patients with re-lapsed low grade non-Hodgkin’s lymphoma. Haematologica. 2001;86:951–8.PubMed
96.
Zurück zum Zitat Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol. 2004;22:4711–6.PubMedCrossRef Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol. 2004;22:4711–6.PubMedCrossRef
97.
Zurück zum Zitat Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimericanti-CD20 (IDEC-c2b8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm. 1997;12:177–86.PubMedCrossRef Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimericanti-CD20 (IDEC-c2b8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm. 1997;12:177–86.PubMedCrossRef
98.
Zurück zum Zitat Mathas S, Rickers A, Bommert K, Dorken B, Mapara MY. Anti-CD20-and B-cell receptor mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res. 2000;60:7170–6.PubMed Mathas S, Rickers A, Bommert K, Dorken B, Mapara MY. Anti-CD20-and B-cell receptor mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res. 2000;60:7170–6.PubMed
99.
Zurück zum Zitat Shan D, Ledbetter JA, Press O. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998;91:1644–52.PubMed Shan D, Ledbetter JA, Press O. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998;91:1644–52.PubMed
100.
Zurück zum Zitat Conconi A, Martinelli G, Thieblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003;102:2741–5.PubMedCrossRef Conconi A, Martinelli G, Thieblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003;102:2741–5.PubMedCrossRef
101.
Zurück zum Zitat Raderer M, Jager G, Brugger S, et al. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology. 2003;65:306–10.PubMedCrossRef Raderer M, Jager G, Brugger S, et al. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology. 2003;65:306–10.PubMedCrossRef
102.
Zurück zum Zitat Lossos IS, Morgensztern D, Blaya M, Alencar A, Pereira D, Rosenblatt J. Rituximab for treatment of chemoimmunotherapy naive marginal zone lymphoma. Leuk Lymphoma. 2007;48:1630–2.PubMedCrossRef Lossos IS, Morgensztern D, Blaya M, Alencar A, Pereira D, Rosenblatt J. Rituximab for treatment of chemoimmunotherapy naive marginal zone lymphoma. Leuk Lymphoma. 2007;48:1630–2.PubMedCrossRef
103.
Zurück zum Zitat Morgensztern D, Rosado MF, Serafini AN, Lossos IS. Somatostatin receptor scintigraphy in MALT lymphoma of the lacrimal gland treated with rituximab. Leuk Lymphoma. 2004;45:1275–8.PubMedCrossRef Morgensztern D, Rosado MF, Serafini AN, Lossos IS. Somatostatin receptor scintigraphy in MALT lymphoma of the lacrimal gland treated with rituximab. Leuk Lymphoma. 2004;45:1275–8.PubMedCrossRef
104.
Zurück zum Zitat Nuckel H, Meller D, Steuhl KP, Duhrsen U. Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva. Eur J Haematol. 2004;73:258–62.PubMedCrossRef Nuckel H, Meller D, Steuhl KP, Duhrsen U. Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva. Eur J Haematol. 2004;73:258–62.PubMedCrossRef
105.
Zurück zum Zitat Ferreri AJ, Ponzoni M, Martinelli G, et al. Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa. Haematologica. 2005;90:1578–9.PubMed Ferreri AJ, Ponzoni M, Martinelli G, et al. Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa. Haematologica. 2005;90:1578–9.PubMed
106.
Zurück zum Zitat Benetatos L, Alymara V, Asproudis I, Bourantas KL. Rituximab as first line treatment for MALT lymphoma of extraocular muscles. Ann Hematol. 2006;85:625–6.PubMedCrossRef Benetatos L, Alymara V, Asproudis I, Bourantas KL. Rituximab as first line treatment for MALT lymphoma of extraocular muscles. Ann Hematol. 2006;85:625–6.PubMedCrossRef
107.
Zurück zum Zitat Heinz C, Merz H, Nieschalk M, Mueller-Miny H, Koch P, Heiligenhaus A. Rituximab for the treatment of extranodal marginal zone B-cell lymphoma of the lacrimal gland. Br J Ophthalmol. 2007;91:1563–4.PubMedPubMedCentralCrossRef Heinz C, Merz H, Nieschalk M, Mueller-Miny H, Koch P, Heiligenhaus A. Rituximab for the treatment of extranodal marginal zone B-cell lymphoma of the lacrimal gland. Br J Ophthalmol. 2007;91:1563–4.PubMedPubMedCentralCrossRef
108.
Zurück zum Zitat Tedder TF, Engel P. CD20: a regulator of cell-type progression of B-lymphocytes. Immunol Today. 1994;15:450–4.PubMedCrossRef Tedder TF, Engel P. CD20: a regulator of cell-type progression of B-lymphocytes. Immunol Today. 1994;15:450–4.PubMedCrossRef
110.
Zurück zum Zitat Ferreri AJ, Ponzoni M, Guidoboni M, et al. Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. J Clin Oncol. 2005;23:5067–73.PubMedCrossRef Ferreri AJ, Ponzoni M, Guidoboni M, et al. Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. J Clin Oncol. 2005;23:5067–73.PubMedCrossRef
111.
Zurück zum Zitat Abramson DH, Rollins I, Coleman M. Periocular mucosa-associated lymphoid/low grade lymphomas: treatment with antibiotics. Am J Ophthalmol. 2005;140:729–30.PubMedCrossRef Abramson DH, Rollins I, Coleman M. Periocular mucosa-associated lymphoid/low grade lymphomas: treatment with antibiotics. Am J Ophthalmol. 2005;140:729–30.PubMedCrossRef
112.
Zurück zum Zitat Grünberger B, Hauff W, Lukas J, et al. ‘Blind’ antibiotic treatment targeting Chlamydia is not effective in patients with MALT lymphoma of the ocular adnexa. Ann Oncol. 2006;17:484–7.PubMedCrossRef Grünberger B, Hauff W, Lukas J, et al. ‘Blind’ antibiotic treatment targeting Chlamydia is not effective in patients with MALT lymphoma of the ocular adnexa. Ann Oncol. 2006;17:484–7.PubMedCrossRef
113.
Zurück zum Zitat Kiesewetter B, Raderer Markus. Antibiotic therapy in non-gastrointestinal MALT lymphoma: a review of the literature. Blood. 2013;122:1350–7.PubMedCrossRef Kiesewetter B, Raderer Markus. Antibiotic therapy in non-gastrointestinal MALT lymphoma: a review of the literature. Blood. 2013;122:1350–7.PubMedCrossRef
114.
Zurück zum Zitat Yoon JS, Ma KT, Kim SJ, Kook K, Lee SY. Prognosis for patients in a Korean population with ocular adnexal lymphoproliferative lesions. Ophthal Plast Reconstr Surg. 2007;23:94–9.PubMedCrossRef Yoon JS, Ma KT, Kim SJ, Kook K, Lee SY. Prognosis for patients in a Korean population with ocular adnexal lymphoproliferative lesions. Ophthal Plast Reconstr Surg. 2007;23:94–9.PubMedCrossRef
115.
Zurück zum Zitat Husain A, Roberts D, Pro B, McLaughlin P, Esmaeli B. Meta-analyses of the association between Chlamydia psittaci and ocular adnexal lymphoma and the response of ocular adnexal lymphoma to antibiotics. Cancer. 2007;110:809–15.PubMedCrossRef Husain A, Roberts D, Pro B, McLaughlin P, Esmaeli B. Meta-analyses of the association between Chlamydia psittaci and ocular adnexal lymphoma and the response of ocular adnexal lymphoma to antibiotics. Cancer. 2007;110:809–15.PubMedCrossRef
116.
Zurück zum Zitat Wenzel C, Fiebiger W, Dieckmann K, Formanek M, Chott A, Raderer M. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue of the head and neck area: high rate of disease recurrence following local therapy. Cancer. 2003;97:2236–41.PubMedCrossRef Wenzel C, Fiebiger W, Dieckmann K, Formanek M, Chott A, Raderer M. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue of the head and neck area: high rate of disease recurrence following local therapy. Cancer. 2003;97:2236–41.PubMedCrossRef
117.
Zurück zum Zitat Zucca E, Conconi A, Pedrinis E, et al. Non gastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood. 2003;101:2489–95.PubMedCrossRef Zucca E, Conconi A, Pedrinis E, et al. Non gastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood. 2003;101:2489–95.PubMedCrossRef
119.
Zurück zum Zitat Meunier J, Lumbroso-Le Rouic L, Vincent-Salomon A, et al. Ophthalmologic and intraocular non-Hodgkin’s lymphoma: a large single centre study of initial characteristics, natural history, and prognostic factors. Hematol Oncol. 2004;22:143–58.PubMedCrossRef Meunier J, Lumbroso-Le Rouic L, Vincent-Salomon A, et al. Ophthalmologic and intraocular non-Hodgkin’s lymphoma: a large single centre study of initial characteristics, natural history, and prognostic factors. Hematol Oncol. 2004;22:143–58.PubMedCrossRef
120.
Zurück zum Zitat Martinet S, Ozsahin M, Belkacemi Y, et al. Outcome and prognostic factors in orbital lymphoma: a Rare Cancer Network study on 90 consecutive patients treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2003;55:892–8.PubMedCrossRef Martinet S, Ozsahin M, Belkacemi Y, et al. Outcome and prognostic factors in orbital lymphoma: a Rare Cancer Network study on 90 consecutive patients treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2003;55:892–8.PubMedCrossRef
121.
Zurück zum Zitat Chaidos AI, Bai MC, Kamina SA, Kanavaros PE, Agnantis NJ, Bourantas KL. Incidence of apoptosis and cell proliferation in multiple myeloma: correlation with bcl-2 protein expression and serum levels of interleukin-6 (IL-6) and soluble IL-6 receptor. Eur J Haematol. 2002;69(2):90–4.PubMedCrossRef Chaidos AI, Bai MC, Kamina SA, Kanavaros PE, Agnantis NJ, Bourantas KL. Incidence of apoptosis and cell proliferation in multiple myeloma: correlation with bcl-2 protein expression and serum levels of interleukin-6 (IL-6) and soluble IL-6 receptor. Eur J Haematol. 2002;69(2):90–4.PubMedCrossRef
122.
Zurück zum Zitat Bai M, Tsanou E, Agnantis NJ, et al. Expression of cyclin D3 and cyclin E and identification of distinct clusters of proliferation and apoptosis in diffuse large B-cell lymphomas. Histol Histopathol. 2003;18(2):449–57.PubMed Bai M, Tsanou E, Agnantis NJ, et al. Expression of cyclin D3 and cyclin E and identification of distinct clusters of proliferation and apoptosis in diffuse large B-cell lymphomas. Histol Histopathol. 2003;18(2):449–57.PubMed
123.
Zurück zum Zitat Korkolopoulou PA, Angelopoulou MK, Kontopidou FN, et al. Retinoblastoma gene product and P21 (WAF1, CIP1) protein expression in non-Hodgkin’s lymphomas: a multivariate survival analysis. Leuk Lymphoma. 2001;40:647–58.PubMedCrossRef Korkolopoulou PA, Angelopoulou MK, Kontopidou FN, et al. Retinoblastoma gene product and P21 (WAF1, CIP1) protein expression in non-Hodgkin’s lymphomas: a multivariate survival analysis. Leuk Lymphoma. 2001;40:647–58.PubMedCrossRef
Metadaten
Titel
Ocular adnexal marginal zone lymphoma of mucosa-associated lymphoid tissue
verfasst von
Dimitrios Kalogeropoulos
Alexandra Papoudou-Bai
Panagiotis Kanavaros
Chris Kalogeropoulos
Publikationsdatum
22.09.2017
Verlag
Springer International Publishing
Erschienen in
Clinical and Experimental Medicine / Ausgabe 2/2018
Print ISSN: 1591-8890
Elektronische ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-017-0474-1

Weitere Artikel der Ausgabe 2/2018

Clinical and Experimental Medicine 2/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.